Second pivotal study of sustained-exposure otic dexamethasone [OTO 104] in patients with Meniere's disease
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2018
Price : $35 *
At a glance
- Drugs Dexamethasone (Primary)
- Indications Meniere's disease
- Focus Registrational; Therapeutic Use
- Sponsors Otonomy
- 08 Mar 2018 According to an Otonomy media release, trial is expected to start in mid 2018.
- 09 Oct 2014 According to an Otonomy media release, OTO-104 has been granted Fast Track designation by the U.S. FDA.
- 12 Dec 2013 New trial record